[go: up one dir, main page]

EE03875B1 - S-omeprasooli uus vorm - Google Patents

S-omeprasooli uus vorm

Info

Publication number
EE03875B1
EE03875B1 EEP199900550A EEP9900550A EE03875B1 EE 03875 B1 EE03875 B1 EE 03875B1 EE P199900550 A EEP199900550 A EE P199900550A EE P9900550 A EEP9900550 A EE P9900550A EE 03875 B1 EE03875 B1 EE 03875B1
Authority
EE
Estonia
Prior art keywords
omeprazole
new form
new
Prior art date
Application number
EEP199900550A
Other languages
English (en)
Estonian (et)
Inventor
Kristina Cotton Hanna
Kronstr�m Anders
Mattson Anders
M�ller Eva
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE9900550A publication Critical patent/EE9900550A/xx
Publication of EE03875B1 publication Critical patent/EE03875B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
EEP199900550A 1997-05-30 1998-05-25 S-omeprasooli uus vorm EE03875B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening
PCT/SE1998/000974 WO1998054171A1 (fr) 1997-05-30 1998-05-25 Nouvelle forme de s-omeprazole

Publications (2)

Publication Number Publication Date
EE9900550A EE9900550A (et) 2000-06-15
EE03875B1 true EE03875B1 (et) 2002-10-15

Family

ID=20407186

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900550A EE03875B1 (et) 1997-05-30 1998-05-25 S-omeprasooli uus vorm

Country Status (43)

Country Link
US (6) US6369085B1 (fr)
EP (2) EP1273581B1 (fr)
JP (2) JP4002303B2 (fr)
KR (2) KR100527804B1 (fr)
CN (1) CN1161351C (fr)
AR (2) AR012717A1 (fr)
AT (2) ATE239011T1 (fr)
AU (1) AU722839B2 (fr)
BR (1) BR9809509A (fr)
CA (2) CA2521391C (fr)
CY (1) CY2012029I1 (fr)
CZ (1) CZ297585B6 (fr)
DE (3) DE69829511T2 (fr)
DK (2) DK0984957T3 (fr)
DZ (1) DZ2495A1 (fr)
EE (1) EE03875B1 (fr)
EG (1) EG24291A (fr)
ES (2) ES2195345T7 (fr)
HR (1) HRP980263B1 (fr)
HU (1) HU225987B1 (fr)
ID (1) ID29306A (fr)
IL (1) IL132947A0 (fr)
IS (2) IS2142B (fr)
LU (2) LU91871I2 (fr)
MA (1) MA26500A1 (fr)
ME (3) ME00198B (fr)
MY (2) MY120745A (fr)
NO (3) NO317518B1 (fr)
NZ (1) NZ500991A (fr)
PL (1) PL193546B1 (fr)
PT (2) PT984957E (fr)
RS (2) RS50067B (fr)
RU (1) RU2184115C2 (fr)
SA (2) SA05260296B1 (fr)
SE (1) SE510650C2 (fr)
SI (2) SI0984957T1 (fr)
SK (2) SK284837B6 (fr)
TN (1) TNSN98074A1 (fr)
TR (1) TR199902934T2 (fr)
TW (1) TW538040B (fr)
UA (1) UA60334C2 (fr)
WO (1) WO1998054171A1 (fr)
ZA (1) ZA984179B (fr)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
EP0909323B1 (fr) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bacterioferritine de helicobacter pilori
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DK1487818T3 (da) 2002-03-05 2007-08-20 Astrazeneca Ab Alkylammoniumsalte af omeprazol og esomeprazol
WO2003089408A2 (fr) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Pyridinylmethyl-sulphinyl-benzimidazole substitue optiquement actif et sels
AU2003247729B2 (en) * 2002-06-27 2009-10-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
WO2004002982A2 (fr) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited Procede de preparation de composes sulfoxyde optiquement purs ou optiquement enrichis, notamment de l'esomeprazole amorphe et ses sels
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CA2501424A1 (fr) * 2002-08-30 2004-03-11 Dr. Reddy's Laboratories Limited Hydrates amorphes d'esomeprazole magnesium et leur procede de preparation
EP1552833B1 (fr) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Procédé de préparation d'un iosmère optiquement actif du lansoprazole
BR0315574A (pt) * 2002-10-22 2005-09-20 Ranbaxy Lab Ltd Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
WO2004046134A2 (fr) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Composes d'esomeprazole cristallins et procede permettant de preparer ces composes
EP1583507A2 (fr) * 2003-01-07 2005-10-12 Ranbaxy Laboratories Limited Sels de magnesium de derives de l'imidazole
WO2004089935A1 (fr) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Nouvelles formes cristallines de s-omeprazole magnesium
EP1633736A1 (fr) 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Sel de baryum d'un derive de benzimidazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528158A (ja) * 2003-07-23 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト プロトンポンプ阻害剤のアルカリ塩
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
BRPI0507784A (pt) * 2004-02-18 2007-07-17 Allergan Inc métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
WO2005082338A2 (fr) * 2004-02-18 2005-09-09 Allergan, Inc. Methodes et compositions d'administration intraveineuse de composes de type inhibiteurs de la pompe a protons
CA2561700A1 (fr) * 2004-04-16 2005-12-15 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
EP1768668A2 (fr) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Forme posologique a doses ppi multiples
CN1972928A (zh) * 2004-06-24 2007-05-30 阿斯利康(瑞典)有限公司 制备用于制备依美拉唑钠盐的结晶修饰物的新方法
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006073779A1 (fr) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Nouvelles formes de l'omeprazole et méthodes correspondantes
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US20090298884A1 (en) * 2005-05-06 2009-12-03 Glenmark Generics Ltd. Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
EP1891043A1 (fr) * 2005-06-15 2008-02-27 Hetero Drugs Limited Ésoméprazole hydraté amorphe
WO2007008588A2 (fr) * 2005-07-07 2007-01-18 Dr. Reddy's Laboratories Ltd. Omeprazole de forme b
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
WO2007031845A2 (fr) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Formes polymorphiques de sels de magnesium de (s)-omeprazole et procedes de preparation desdites formes
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
JP5017274B2 (ja) * 2005-10-26 2012-09-05 ハンミ・サイエンス・カンパニー・リミテッド Ｓ−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物
EP1801110A1 (fr) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Sel d'arginine d'ésoméprazole
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US20100286208A1 (en) * 2006-06-21 2010-11-11 Bobba Venkata Siva Kumar Novel polymorph of esomeprazole potassium and process for its preparation
WO2008067037A2 (fr) 2006-10-05 2008-06-05 Santarus, Inc. Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
EP1947099A1 (fr) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Procédé pour l'élimination de solvant des sels d'oméprazole
EP2114919A2 (fr) 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation d'oméprazole optiquement pur
EP2186807B1 (fr) * 2007-02-21 2015-01-07 Cipla Limited Procédé pour la préparation de ésoméprazole magnésium dihydraté
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (fr) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Sels d'ésoméprazole et procédés pour leur préparation
ATE534643T1 (de) * 2007-06-07 2011-12-15 Aurobindo Pharma Ltd Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
BRPI0818286A2 (pt) 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
WO2009074997A2 (fr) * 2007-12-10 2009-06-18 Lee Pharma Ltd. Nouveau procédé de préparation de sel de magnésium cristallin de (s)-oméprazole dihydraté
WO2009099933A2 (fr) * 2008-02-01 2009-08-13 Dr. Reddy's Laboratories Ltd. Préparation de magnésium d’ésoméprazole et de ses hydrates
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2143722A1 (fr) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Procédé de préparation de sodium ésoméprazole de haute pureté chimique et nouvelles formes de sodium ésoméprazole
EP2147918A1 (fr) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Procédé de préparation de magnésium d'oméprazole S dans une forme stable
CN102209529A (zh) 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (fr) 2009-02-24 2010-09-02 Cipla Limited Polymorphe de l'ésoméprazole de potassium et sa préparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (fr) 2009-04-24 2010-10-28 Rubicon Research Private Limited Compositions pharmaceutiques orales comprenant des substances labiles en milieu acide
EP2438057A4 (fr) * 2009-06-02 2013-12-25 Sun Pharmaceutical Ind Ltd Procédé d'élaboration de composés sulfoxyde
CN102481293A (zh) 2009-06-25 2012-05-30 阿斯利康(瑞典)有限公司 治疗具有发展nsaid-相关的溃疡的风险的患者的方法
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
WO2011012957A1 (fr) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd Procédé perfectionné pour la préparation d'ésoméprazole magnésique dihydraté
WO2011058569A1 (fr) 2009-11-12 2011-05-19 Hetero Research Foundation Procédé de dédoublement de l'oméprazole
CN102884178B (zh) 2009-12-08 2014-12-03 科德克希思公司 拉唑化合物的合成
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
EP2649187B1 (fr) 2010-12-08 2017-11-22 Codexis, Inc. Biocatalyseurs et procédés de synthèse de l'armodafinil
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102924435B (zh) * 2011-11-25 2014-06-25 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (fr) * 2011-12-14 2013-06-20 Wockhardt Limited Composition pharmaceutique comprenant du dihydrate de magnésium d'ésoméprazole
WO2013101897A2 (fr) 2011-12-28 2013-07-04 Pozen Inc. Compositions et procédés d'administration d'oméprazole plus acide acétylsalicylique améliorés
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) * 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
JP7506892B2 (ja) * 2018-08-21 2024-06-27 東和薬品株式会社 化合物の特定形状の結晶及びその製造方法
WO2020040438A1 (fr) 2018-08-23 2020-02-27 주식회사 종근당 Préparation pharmaceutique ayant d'excellentes propriétés de dissolution, contenant de l'ésoméprazole et du bicarbonate de sodium
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制
CN119320380B (zh) * 2024-10-14 2025-11-25 山东益康药业股份有限公司 奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途
CN119320381B (zh) * 2024-10-14 2025-12-12 山东益康药业股份有限公司 奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US5244891A (en) 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
CZ289804B6 (cs) 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
ATE199375T1 (de) 1994-11-14 2001-03-15 Daiichi Seiyaku Co Verfahren zur herstellung von 3-(2-(4-(3-chlor-2- methylphenyl)-1- piperazinyl) ethyl)-5,6- dimethoxy-1-(4-imidazolylmethyl)-1h-indazol- dihydrochlorid-3.5-hydrat.
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6747155B2 (en) * 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
MY120745A (en) 2005-11-30
SI0984957T1 (en) 2003-10-31
US20050075369A1 (en) 2005-04-07
NO995852D0 (no) 1999-11-29
UA60334C2 (uk) 2003-10-15
NO2011010I1 (no) 2011-06-20
NO2012011I1 (no) 2012-06-18
ZA984179B (en) 1998-11-30
MEP18008A (en) 2010-10-10
SK162599A3 (en) 2000-06-12
EP1273581B1 (fr) 2005-03-23
NZ500991A (en) 2001-05-25
HRP980263A2 (en) 1999-02-28
SK284837B6 (sk) 2005-12-01
JP2007161734A (ja) 2007-06-28
ID29306A (id) 2001-08-16
EP0984957B3 (fr) 2013-09-18
NO317518B1 (no) 2004-11-08
SE510650C2 (sv) 1999-06-14
US6369085B1 (en) 2002-04-09
KR100540720B1 (ko) 2006-01-12
WO1998054171A8 (fr) 1999-12-23
IS8368A (is) 2006-03-22
TNSN98074A1 (fr) 2005-03-15
YU60999A (sh) 2002-03-18
IS2142B (is) 2006-09-15
LU91871I2 (fr) 2011-11-21
ME00198B (me) 2011-02-10
AR059589A2 (es) 2008-04-16
CN1161351C (zh) 2004-08-11
DK0984957T3 (da) 2003-06-30
CN1258295A (zh) 2000-06-28
EP1273581A1 (fr) 2003-01-08
DK1273581T3 (da) 2005-06-06
US6677455B2 (en) 2004-01-13
CA2521391A1 (fr) 1998-12-03
RS20070459A (sr) 2008-06-05
EP0984957A1 (fr) 2000-03-15
LU92017I2 (fr) 2012-08-06
HU225987B1 (en) 2008-02-28
KR20050042827A (ko) 2005-05-10
CY2012029I2 (el) 2015-08-05
DE69829511D1 (de) 2005-04-28
CY2012029I1 (el) 2015-08-05
EE9900550A (et) 2000-06-15
ATE239011T1 (de) 2003-05-15
RS50067B (sr) 2009-01-22
US20120252847A1 (en) 2012-10-04
IS2774B (is) 2012-03-15
ES2195345T7 (es) 2014-01-15
HRP980263B1 (en) 2002-02-28
CZ297585B6 (cs) 2007-01-10
HK1025962A1 (en) 2000-12-01
SA05260296B1 (ar) 2008-04-16
JP2002501529A (ja) 2002-01-15
DE122012000017I1 (de) 2012-08-16
US7745466B2 (en) 2010-06-29
MY127793A (en) 2006-12-29
EP0984957B1 (fr) 2003-05-02
TR199902934T2 (xx) 2000-04-21
CA2290963A1 (fr) 1998-12-03
DE69814069T3 (de) 2014-03-27
PT1273581E (pt) 2005-06-30
ES2236407T3 (es) 2005-07-16
IS5272A (is) 1999-11-25
US8466175B2 (en) 2013-06-18
SE9702065L (sv) 1998-12-01
KR100527804B1 (ko) 2005-11-15
SE9702065D0 (sv) 1997-05-30
TW538040B (en) 2003-06-21
DZ2495A1 (fr) 2003-01-25
HUP0001849A3 (en) 2003-02-28
BR9809509A (pt) 2000-06-20
AR012717A1 (es) 2000-11-08
MEP24908A (en) 2010-10-10
US20110130570A1 (en) 2011-06-02
US7411070B2 (en) 2008-08-12
SI1273581T1 (fr) 2005-08-31
SK285137B6 (sk) 2006-07-07
RS50005B (sr) 2008-09-29
US8076361B2 (en) 2011-12-13
JP4002303B2 (ja) 2007-10-31
MA26500A1 (fr) 2004-12-20
ES2195345T3 (es) 2003-12-01
AU7793598A (en) 1998-12-30
DE69829511T2 (de) 2006-02-16
PL337180A1 (en) 2000-08-14
HUP0001849A2 (hu) 2002-05-29
US20020198239A1 (en) 2002-12-26
EG24291A (en) 2009-01-08
CA2521391C (fr) 2009-09-29
AU722839B2 (en) 2000-08-10
DE69814069T2 (de) 2004-04-01
DE69814069D1 (de) 2003-06-05
PL193546B1 (pl) 2007-02-28
KR20010013126A (ko) 2001-02-26
HK1051681A1 (en) 2003-08-15
WO1998054171A1 (fr) 1998-12-03
HU0001849D0 (fr) 2002-05-29
US20080255363A1 (en) 2008-10-16
PT984957E (pt) 2003-07-31
RU2184115C2 (ru) 2002-06-27
ATE291574T1 (de) 2005-04-15
IL132947A0 (en) 2001-03-19
NO995852L (no) 2000-01-31
SA98190280B1 (ar) 2006-07-04
CA2290963C (fr) 2006-03-28

Similar Documents

Publication Publication Date Title
EE03875B1 (et) S-omeprasooli uus vorm
EE9900259A (et) Ühendi uus vorm
IS6239A (is) Ný efnasambönd
NO20000677D0 (no) Brønnhode
NO20002571D0 (no) Emballasje
DE60008769D1 (de) Spender
DE60012154D1 (de) Zange
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DK1261585T3 (da) Substituerede indol-Mannichbaser
IS6139A (is) Ný efnasambönd
PT1237857E (pt) Novos derivados fenalquiloxi-fenilo
NO20015510D0 (no) Medikament for lokal påföring
EE200000022A (et) Uus ravimvorm
EE9900391A (et) Uus protsess
DE60037421D1 (de) Stopfbuchspackung
DE50006616D1 (de) Zange
IS6141A (is) Ný efnasambönd
IT249842Y1 (it) Fissaggio a incastro per un cassetto sospeso
DK1317256T3 (da) Farmaceutisk sammensætning havende en modificeret bærer
DE50106325D1 (de) Liganden von integrinrezeptoren
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
EE200100381A (et) Morfolinobensamiidi uued soolad
DE60037420D1 (de) Stopfbuchspackung
EE9900455A (et) Uus menetlus
DE50008657D1 (de) Verpackungsklebebänder

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
AA1Y Spc filed

Free format text: PRODUCT NAME: VIMOVO; REG NO/DATE: 714110 23.11.2010

Spc suppl protection certif: C20110007

Filing date: 20110516

FG1Y Spc granted

Free format text: PRODUCT NAME: VIMOVO;REG NO/DATE: 714110 23.11.2010

Spc suppl protection certif: C20110007 00061

Filing date: 20110516

Extension date: 20230525

Free format text: PRODUCT NAME: VIMOVO;REG NO/DATE: 714110 23.11.2010

Spc suppl protection certif: C20110007 00061

Filing date: 20110516

Extension date: 20310516